Abstract: 　Glanzmann thrombasthenia (GT) is an inherited disease of platelet function disorders characterized by mucocutaneous bleeding due to platelets failed to aggregate in response to physiologic stimuli. GT is a rare inherited disease and caused by quantitative or qualitative deficiencies of an integrin receptor GP Ⅱb/Ⅲa for adhesive proteins. There is no unified treatment strategy available so far for GT. This review summarizes the update of pathogenesis treatment progresses in GT.